TON - October 2011 Vol 4 No 7

TON - October 2011 Vol 4 No 7 — October 19, 2011

SAN FRANCISCO—A number of interventions can help reduce breast cancer among women at high risk, but uptake is sluggish, and there can be confusion about which agent to prescribe to a given patient. Seema Khan, MD, professor of surgery at Northwestern University Feinberg School of Medicine, Chicago, addressed the topic of pharmacologic risk reduction at the 2011 Breast Cancer Symposium.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

Although there is no straightforward answer to this question, the current recommended daily allowances for adults—600 IU for children and adults, and 800 IU for those older than 70 years— are probably too low.1,2 To provide a little background, vitamin D should be considered a prohormone rather than a vitamin (a substance humans need in small amounts and usually cannot synthesize).3 Animals convert 7-hydrocholesterol to calciferol (D3) in the dermis via a photochemical reaction with ultraviolet B (UVB) sunlight. Read More ›


TON - October 2011 Vol 4 No 7 — October 19, 2011

CHICAGO—Screening all patients for hepatitis B surface antigen (HBsAg) before initiating chemotherapy for lymphoma is associated with improved clinical outcomes and is economically favorable, according to an analysis presented by researchers at the University of Toronto and St Michael’s Hospital, Toronto, Ontario, at the annual meeting of the American Society of Clinical Oncology.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

CHICAGO—Targeted drugs are very effective in patients with a well-specified molecular target. Examples include imatinib in patients with chronic myelog enous leukemia and trastuzumab in HER2-positive breast cancer. Evidence, however, has shown only modest improvements in outcomes when targeted agents are given to “unselected patients,” that is, those lacking a tumor characteristic (or mutation) that is specifically addressed by a given drug. Read More ›


TON - October 2011 Vol 4 No 7 — October 19, 2011

The National Women’s Hall of Fame recently inducted Loretta C. Ford, RN, EdD, PNP, FAAN, FAANP, along with 10 other American women who have made valuable and enduring contributions to our nation. These women were formally inducted on September 30 and October 1, 2011, in Seneca Falls, New York, the birthplace of the American Women’s Rights Movement.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

WASHINGTON, DC—Psychosocial stress may play a role in the etiology of breast cancer aggressiveness, particularly among minority populations, according to study results. In a cross-sectional study, greater levels of fear, anxiety, or isolation were found to be associated with more aggressive breast cancer; however, no clear driver for the association is yet identified.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

The following articles are based on presentations at the Fourth American Association for Cancer Research Conference on The Science of
Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved held September 18-21, 2011, in Washington, DC


WASHINGTON, DC—The overall incidence of breast cancer is generally higher among white women than black women. The incidence of a second breast cancer in the opposite breast, however, is higher among black women, according to new data.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

After a long series of treatments for stage IV ovarian cancer, I finished my last chemotherapy session in March 2010. About 2 months later, I realized I missed the camaraderie and friendships I had developed during the hours of waiting for the chemotherapy to be administered. I looked for a support group and soon joined the Scripps GYN Support Group that meets twice monthly. By that point, I had started sharing the story of my journey with ovarian cancer, finding that others were helped when they heard it.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

SAN ANTONIO—A rapidly growing, nationwide clinical trial matching service that is user-friendly for patients is enabling more patients to learn about and enroll in clinical trials, said Ellie Cohen, PhD, the program’s director. Cohen described the success of her program at the 33rd annual San Antonio Breast Cancer Symposium.

Read More ›

TON - October 2011 Vol 4 No 7 — October 19, 2011

CHICAGO—In the National Cancer Institute of Canada Clinical Trials Group MA.20 trial, regional nodal irradiation (RNI) added to whole breast irradiation (WBI) improved disease- free survival (DFS), with a trend toward improved overall survival (OS), reported Timothy Whelan, MD, of McMaster University and the Juravinski Cancer Centre in Hamilton, Ontario.

Read More ›

Page 1 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: